THSNA 2026 - Portland, OR

PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

Workshop Schedule

SATELLITE SYMPOSIA

Host a Satellite Symposium

Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2026 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.

Wed - Mar 18

Thu - Mar 19

Fri - Mar 20

Sat - Mar 21

View Program Details

THURSDAY, MARCH 19

7:00 - 8:00 AM

SATELLITE SYMPOSIUM

A MEDICAL FORUM FOR EVIDENCE, EXPERIENCE, AND INTERACTIVE DIALOGUE ON CONTEMPORARY CONSIDERATIONS IN HEMOPHILIA CARE (SPONSORED BY SANOFI)
B113-114

Hemophilia care is entering a transformative era, with growing emphasis on how clinical approaches can support the individual needs and treatment goals of patients. Join leading experts and peers for a dynamic and educational program featuring interactive dialogue across a range of topics, including case-based scenarios, evolving management strategies, and the broader aspirations of people living with hemophilia. This forum will provide real-world perspectives and practical insights from clinical practice, fostering thoughtful, balanced discussion to support healthcare professionals in considering a range of evidence-based strategies as they collaborate with patients in todays changing therapeutic environment. Submit Pre Questions here: https://www. surveymonkey. com/r/XPRQLLR

ADVANCING HEMOPHILIA CARE THROUGH TFPI INHIBITION: CLINICAL EVIDENCE AND EMERGING REAL-WORLD EXPERIENCE WITH HYMPAVZI (MARSTACIMAB) (SPONSORED BY PFIZER INC)
B115-116

Non‑factor therapies continue to reshape the treatment landscape for hemophilia by offering novel approaches to rebalancing coagulation. Hympavzi (marstacimab), a subcutaneously administered anti‑TFPI therapy, represents an important new option informed by both robust clinical data and emerging real‑world experience. This symposium will explore the scientific rationale, mechanism of action, clinical trial evidence, and practical considerations surrounding the use of Hympavzi (marstacimab) in hemophilia management. Faculty will review the foundational science behind Hympavzi (marstacimab) and summarize key findings from the Phase 3 clinical development program. In addition, the session will feature a discussion with hematologists who have real‑world experience integrating Hympavzi (marstacimab) into clinical practice. Their perspectives on patient selection, breakthrough bleeds, surgical data, monitoring, and initial outcomes will provide attendees with practical insights into how Hympavzi (marstacimab) may be incorporated into the evolving therapeutic landscape of hemophilia care.

7:00 - 6:30 PM

EVENT/OTHER

REGISTRATION
Oregon Ballroom Lobby

8:15 - 9:45 AM

PLENARY SESSION

IS DEI DOA?
Chair/Organizer: Julie Jaffray, Anne Rose
Oregon Ballroom 201

8:15

WELCOME TO THSNA 2026.

8:30

MEDICINE DEI
BETHANY SAMUELSON BANNOW.

8:55

DEI IN HEALTHCARE ACCESS
KERI NORRIS.

9:20

CAREER DEI
DEE TERRELL.

9:45 - 10:30 AM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Exhibit Hall A

A1. ANTICOAGULATION CLINICS

100

A QUALITATIVE STUDY OF WARFARIN SELF-MANAGEMENT IN THE UNITED STATES HEALTHCARE SYSTEM: INSIGHTS FROM PATIENT EXPERIENCES
SPENCER J. GILBERT^{1, 2}, HEESEUNG HONG¹, AUBREY E. JONES^{1, 2}, SARA R. VAZQUEZ^{1, 2}, GEOFFREY D. BARNES³, KATELYN W. SYLVESTER⁴, DANIEL M. WITT^{1, 2}. ¹University of Utah College of Pharmacy, Salt Lake City, UT, USA. ²University of Utah Health Thrombosis Service, Salt Lake City, UT, USA. ³University of Michigan, Ann Harbor, MI, USA. ⁴Brigham and Women's Hospital, Boston, MA, USA

A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION

101

LOW-DOSE PLASMA-DERIVED VON WILLEBRAND FACTOR CONCENTRATE FOR SURGICAL PROPHYLAXIS IN EHLERS-DANLOS SYNDROME WITH NORMAL VWF PROFILES AND DESMOPRESSIN CONTRAINDICATIONS
JOSEPH STANCO, SUCHITRA ACHARYA. Northwell Health, New Hyde Park, NY, and Cohen Childrena, Queens, NY, USA

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

102

HEPARIN INDUCED THROMBOCYTOPENIA IN CARDIAC SURGERY PATIENTS- A NATIONAL INPATIENT SAMPLE DATABASE STUDY FROM 2016-2021
SRUTHI/P RAMANAN¹, KALAIVANI BABU², SRINISHANT RAJARAJAN², YIN YUE³, DEEP SHAH¹. ¹AHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. ²Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA, USA. ³Allegheny Health Network, Pittsburgh, PA, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

103

COAGULATION PARAMETERS AFTER ADMINISTRATION OF BT524, FIBRINOGEN CONCENTRATE FROM HUMAN PLASMA, FOR THE TREATMENT AND PROPHYLAXIS OF BLEEDING IN PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY: AN OPEN-LABEL PHASE I/III STUDY
CLAUDIA DJAMBAS KHAYAT¹, AMAL EL-BESHLAWY², EMNA GOUIDER BELHADJALI³, ABDERRAHIM KHELIF ⁴, SONIA ADOLF⁵, WOLFGANG MIESBACH⁶, HEIKE BOEHM⁷, SILKE AIGNER⁷, SALOMON ABRAHA⁷, FABIAN BOHLAENDER⁷, JOERG SCHUETTRUMPF^{7, 8}. ¹Department of Pediatrics, Hotel Dieu de France Hospital Beirut, Saint Joseph University, Beirut, Lebanon. ²Pediatric Hospital CU, Egyptian Thalassemia Association, El Cairo, Egypt. ³Hospital Aziza Othmana, Tunis, Tunisia. ⁴Farhat Hached Hospital, Ibn El Jazzar Faculty of Medicine, Sousse University, Sousse, Tunisia. ⁵National Research Center, Pediatric Hematology Department, El Cairo, Egypt. ⁶Department of Hemostasis/Hemophilia Centre, Medical Clinic 2, University Hospital Frankfurt, Frankfurt, Germany. ⁷Biotest AG, Dreieich, Germany. ⁸Grifols, Barcelona, Spain

104

CLOTTING POTENTIAL OF A NOVEL MESOPOROUS BIOACTIVE GLASS ABSORBABLE AND ANTIMICROBIAL HEMOSTATIC AGENT
KEITH A. MOSKOWITZ^{1, 2}, SCOTT JANIS², EMILY ALHASSAN², JOHN WALDO³, MARK TOWLER³, PEDRO ABRANTES⁴, VANESSA JOOSTE⁴, BRETT JANIS². ¹KA Bioscience Consultants, LLC, Westfield, IN, USA. ²DesiCorp Inc, Louisville, KY, USA. ³Missouri University of Science a Technology, Rolla, MO, USA. ⁴University of the Western Cape, Cape Town, South Africa

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

105

OUTCOMES OF MARSTACIMAB IN NORTH AMERICAN PARTICIPANTS WITH HEMOPHILIA A AND B WITHOUT INHIBITORS: SUBANALYSIS OF THE PHASE 3 BASIS TRIAL
ANJALI A¹, PENGLING ², JENNIFER ³, TRAVIS ³, ANDREW ⁴. ¹Stead Family Department of Pediatrics, Carver School of Medicine, University of Iowa, Iowa City, IA, USA. ²Pfizer Inc, Cambridge, MA, USA. ³Pfizer Inc, New York, NY, USA. ⁴Pfizer Inc, Collegeville, PA, USA

106

EXPLORATORY ANALYSIS FROM HAVEN 1-4 TO FURTHER CONTEXTUALIZE INJECTION-SITE REACTIONS AMONG PEOPLE WITH HEMOPHILIA A RECEIVING EMICIZUMAB
MAYA BLOOMBERG¹, KATHERINE EAKLE², MARKUS NIGGLI³, CHRISTOPHE DHALLUIN³, LUCY LEE², ELISE LIM², SHANNON L. CARPENTER⁴. ¹Sylvester Comprehensive Cancer Center, Miami, FL, USA. ²Genentech, Inc, South San Francisco, CA, USA. ³F. Hoffmann-La Roche Ltd, Basel, Switzerland. ⁴Childrena, Kansas City, MT, USA

107

IRON DEFICIENCY AND SYMPTOM BURDEN IN PATIENTS WITH HEAVY MENSTRUAL BLEEDING
MAHALYA GOGERLY-MORAGODA, MD¹, SUPREET KAUR GORAYA, MPH, IBCLC^{2, 3}, ALICE MA, MD, FACP^{2, 3}, CALLIE BERKOWITZ, MD^{2, 3}. ¹Internal Medicine Residency Program, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. ²Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. ³Blood Research Center, University of North Carolina, Chapel Hill, NC, USA

108

PATIENT- AND CAREGIVER-REPORTED OUTCOMES WITH SUBCUTANEOUS MIM8 PROPHYLAXIS IN PEDIATRIC PATIENTS WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS: PHASE 3 FRONTIER3 STUDY
GILI KENET¹, MATTEO LUCIANI², PAULA KJAPLLERSTRAPM³, RUBACN BERRUECO⁴, AMALIE RHODE HACGH NIELSEN⁵, JAY JAY THAUNG ZAW⁵, EMILY WATERS⁶, KARIN FIJN VAN DRAAT⁷, RYAN RODRIGUEZ⁶. ¹National Hemophilia Center and Institute of Thrombosis a Hemostasis, Sheba Medical Center, Tel Aviv, Israel. ²Onco-Hematology, Cell and Gene Therapy and Bone Marrow Transplant Clinic Area, Bambino GesA¹ Childrena, Rome, Italy. ³Pediatric Hematology Unit, Hospital Dona EstefAcnia, ULS SApo JosAc, Lisbon, Portugal. ⁴Pediatric Hematology Department, Hospital Sant Joan de DAcu, Universitat de Barcelona, Barcelona, Spain. ⁵Novo Nordisk A/S, SAcborg, Denmark. ⁶Novo Nordisk Inc, Plainsboro, NJ, USA. ⁷Department of Paediatric Haematology, Emma Childrena, Amsterdam, Netherlands

109

MAINTAINING FACTOR VIII TOLERANCE IN PATIENTS WITH SEVERE HEMOPHILIA A ON EMICIZUMAB: A FOUR-PATIENT CASE SERIES
EMILY E MASON, AMY DUNN. Nationwide Children's Hospital, Columbus, OH, USA

111

INSIGHTS INTO EFFECTIVE IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A PATIENTS WITH INHIBITORS:NEW FINDINGS FROM THE INTERIM ANALYSIS OF THE MOTIVATE STUDY
ROBERT F. SIDONIO, JR. ¹, CARMEN ESCURIOLA ETTINGSHAUSEN². ¹Associate Professor of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA. ²HZRM HAcmophilie Zentrum Rhein Main, Frankfurt, Germany

112

ALTERED BASELINE FIBRINOLYTIC ACTIVITY IN LUNG CANCER PATIENTS: A FUNCTIONAL ASSESSMENT USING PLASMA LYSIS TIME AND FIBRINOLYTIC MARKERS
ANUHA VELLANKI¹, PRAKASH KEMPAIAH¹, ALEXANDER POHLMAN^{1, 2}, FAKIHA SIDDIQUI¹, WALTER JESKE ¹, DEBRA HOPPENSTEADT¹, JEANINE WALENGA¹, W. KEITH JONES¹, JEAN AMIRAL¹, JAWED FAREED¹, ZAID ABDELSATTAR¹. ¹Loyola Univeristy Chicago, Maywood, IL, USA. ²University of Illinois Chicago College of Medicine, Chicago, IL, USA

A7. PATHOPHYSIOLOGY OF THROMBOSIS

113

THE POTENTIAL OF SILVER NANOPARTICLES AS ANTIBACTERIAL AGENTS IN THE MANAGEMENT OF VTE FOLLOWING PRE-ECLAMPSIA
MANASVI KONDAMUDI¹, AARAV KESKAR¹, ATUL LADDU¹, JAWED FAREED². ¹Global Thrombosis Forum, Suwanee, GA, USA. ²Loyola University, Chicago, IL, USA

A8. ANTITHROMBOTIC THERAPY

114

AI-DRIVEN DYNAMIC PATIENT AVATARS WITH RECURRENT THROMBOSIS AND INHERITED THROMBOPHILIA: A SCALABLE SIMULATION TOOL FOR PHYSICIAN TRAINING AND HANDOFF
ANVI AGARWAL¹, ASMI AGARWAL¹, ELIJAH ELDRIM², ANDREW PRIMOUS², YANHUI GUO³, RUCHIKA GOEL^{4, 5}, RICHARD SELINFREUND⁶. ¹McNeese P4 (Physician Preparatory Pathway Program), SIU School of Medicine, Springfield, IL, USA. ²Medical Microbiology and Immunology, SIU School of Medicine, Springfield, IL, USA. ³Department of Computer Science, University of Illinois Springfield, Springfield, IL, USA. ⁴Division of Hematology/Oncology, Simmons Cancer Institute, SIU School of Medicine, Springfield, IL, USA. ⁵Department of Pathology, Johns Hopkins University, Baltimore, MD, USA. ⁶Departments of Medical Microbiology, Cell Biology and Immunology, and Medical Education, Springfield, IL, USA

115

QUANTIFYING INAPPROPRIATE ANDEXANET ALFA USE PRIOR TO INSTITUTIONAL POLICY REVISION: A REVIEW OF FIFTY CONSECUTIVE ADMINISTRATIONS
ALIFYA ALTAF LOKHANDWALA, FILIP SADURSKI, ROHIT SHARMA, MONIKA ONUSSEIT, ELLEN ARRINGTON, SARAH BENMIR, MOOSA ALHODA, ABDULRAHMAN ALYOUNES ALAYOUB, MISHEL PAPALI, MATTHEW BASCIOTTA. Department of Medicine, Salem Hospital, Mass General Brigham, Salem, MA, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

117

DEVELOPMENT AND IMPLEMENTATION OF A SCREENING TOOL TO REDUCE BLEED RISK ASSOCIATED WITH ANTIPLATELET USE IN ANTICOAGULATION CLINIC PATIENTS
MATTHEW J. DESCHEPPER, JENNIFER HARDMAN, MEGAN GALLAGHER, HANNAH BREIDENBACH, MICHELLE TE RONDE. Froedtert a the Medical College of Wisconsin, Milwaukee, WI, USA

119

CASE REPORT OF A PEDIATRIC PATIENT WITH CONGENITAL FACTOR VII DEFICIENCY (4%) USING HUMAN RECOMBINANT FACTOR VIIA EPTACOG-BETA AS SECONDARY PROPHYLAXIS
ASHLEY WEHRLE¹, ANUJ KAUL¹, CLAYTON KUBRICK¹, NICOLETTA MACHIN^{1, 2}, CRAIG SEAMAN^{1, 2}, FREDERICO XAVIER^{1, 2}. ¹the Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA. ²University of Pittsburgh, Pittsburgh, PA, USA

10:30 - 11:30 AM

SHORT TALKS

SHORT TALKS - ANTICOAGULATION CLINICS IN ACTION: PRECISION, PROTECTION, AND PERSONALIZATION
Chair/Organizer: Daniel C. Malone, Dan Witt
Oregon Ballroom 203

10:30

EVALUATING THE INDIRECT INTERACTION BETWEEN GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS AND WARFARIN USING REAL-WORLD DATA
SPENCER J. GILBERT^{1, 2, 3}, SARA R. VAZQUEZ^{1, 2}, ALEXANDER MILLAR³, RAMKIRAN GOURIPEDDI³, JULIO C. FACELLI³, DANIEL M. WITT^{1, 2}. ¹University of Utah College of Pharmacy, Salt Lake City, UT, USA. ²University of Utah Health Thrombosis Service, Salt Lake City, UT, USA. ³University of Utah Department of Biomedical Informatics, Salt Lake City, UT, USA

10:42

A NOVEL APPROACH TO ESTIMATING THE RISK OF GASTROINTESTINAL BLEEDING FOR PATIENTS ON ORAL ANTICOAGULANTS AND OTHER MEDICATIONS INCLUDING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND ANTIDEPRESSANTS
DANIEL C. MALONE¹, AINHOA GOMEZ-LUMBRERAS¹, ABDELRAHMAN G. TAWFIK¹, DANIEL M. WITT¹, GUILHERME DEL FIOL², THOMAS REESE³. ¹Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA. ²3Department of Biomedical Informatics, School of Medicine, University of Utah, Salt Lake City, UT, USA. ³Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA

10:54

VALIDATION OF THE DIOAC-GIB MODEL FOR PREDICTING GASTROINTESTINAL BLEEDING IN ANTICOAGULATED PATIENTS: COMPARISON TO THE ALFALFA MODELS FOR WARFARIN AND DOACS
ABDELRAHMAN G. MALONE¹, DANIEL C. MALONE¹, AINHOA GOMEZ. -LUMBRERAS¹, DANIEL M. WITT¹, GUILHERME DEL FIOL². ¹Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA. ²3Department of Biomedical Informatics, School of Medicine, University of Utah, Salt Lake City, UT, USA

11:06

OPTIMIZING ANTICOAGULATION IN PREGNANT WOMEN WITH PROSTHETIC HEART VALVES: A PROSPECTIVE COMPARATIVE STUDY FROM A PHARMACIST-LED CLINIC IN PAKISTAN
GUL SAMA^{1, 2}, ALI HAMZA¹. ¹A¹ Department of Healthcare Management, Faculty of Business Management Sciences, Concordia University Chicago, Chicago, Illinois, USA, Chicago, IL, USA. ²National Institute of Cardivascular Diseases, KARACHI, Pakistan. ³Department of pharmaceutical sciences, Faculty of Pharmacy Institute of Pharmaceutical sciences, Jinnah Sindh Medical university, Karachi, KARACHI, Pakistan

11:18

OVERCOMING BARRIERS TO WARFARIN PATIENT SELF-MANAGEMENT IN THE US HEALTHCARE SYSTEM (THSNATRAVEL AWARDEE)
DANIEL M. WITT^{1, 2}, HEESEUNG HONG^{1, 2}, AARON S. WILSON¹, AUBREY E. JONES^{1, 2}, SARA R. VAZQUEZ^{1. 2}, SPENCER GILBERT^{1, 2}, DANIEL C. MALONE¹, NATHORN CHAIYAKUNAPRUK^{1, 3}, JORDAN B. KING^{4, 5}, GEOFFREY D. BARNES⁶, KATELYN W. SYLVESTER⁷, LINH CHAN⁸, THOMAS DELATE⁹. ¹University of Utah College of Pharmacy, Salt Lake City, UT, USA. ²University of Utah Health Thrombosis Service, Salt Lake City, UT, USA. ³IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USA. ⁴University of Utah School of Medicine, Salt Lake City, UT, USA. ⁵Institute for Health Research kaiser Permanente Colorado, Aurora, CO, USA. ⁶University of Michigan, Ann Arbor, MI, USA. ⁷Brigham and Women's Hospital, Boston, MA, USA. ⁸Loma Linda Veterans Affairs Healthcare System, Loma Linda, CA, USA. ⁹Kaiser Permanente National Pharmacy, Aurora, CO, USA

SHORT TALKS - INSIGHTS INTO THROMBOSIS: RISK FACTORS, MECHANISMS, AND DIAGNOSTIC APPROACHES
Chair/Organizer: Rushad Patell, Kavya Balusu
Oregon Ballroom 201

10:30

IRON DEFICIENCY CAN INCREASE THE RISK OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED PATIENTS WITH POLYCYTHEMIA VERA: A NATIONWIDE ANALYSIS (THSNATRAVEL AWARDEE)
KAVYA BALUSU, PURVA SHAH, CANDRIKA D. KHAIRANI, PETER KOUIDES. Rochester General Hospital, Rochester, NY, USA

10:42

COMPARATIVE EFFECTIVENESS OF APIXABAN AND RIVAROXABAN FOR STROKE PREVENTION IN PATIENTS WITH OBESITY WITH ATRIAL FIBRILLATION: A RETROSPECTIVE COHORT STUDY
PEDRO LUIZ L. B. DANIELIAN¹, URSULA M. A. DE MATOS², SAMANTHA J. NEESON¹, AARTI H. ASNANI¹, PATRICIA TUNG¹, RUSHAD PATELL¹. ¹Beth Israel Deaconess Medical Center, Boston, MA, USA. ²University of Connecticut School of Medicine, Farmington, CT, USA

10:54

FACTOR X DEFICIENCY DOES NOT FULLY RECAPITULATE THE EFFECTS OF PROTHROMBIN KNOCKDOWN ON PODOCYTOPATHY DURING PROTEINURIC GLOMERULAR DISEASE (THSNATRAVEL AWARDEE)
KAUSHIK MURALIDHARAN¹, AMANDA WALLER¹, KATELYN WOLFGANG¹, MAYRA OSEGUERA¹, EMAN ABDELGHANI², BRITTNEY SPRUILL¹, BRYCE KERLIN^{1, 3}. ¹Center for Clinical and Translational Research, Abigail Wexner Research Institute at Nationwide Childrens Hospital, Columbus, OH, USA. ²Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. ³Faculty of Medicine at The Ohio State University, Columbus, OH, USA

11:06

DROSOPHILA MELANOGASTER POTENTIAL MODEL FOR THROMBOSIS
FAKIHA SIDDIQUI¹, SYED MOHAMMAD OMER KHALID², NUSRAT JABEEN³, MUSHTAQ HUSSAIN⁴, JAWED FAREED¹. ¹Department of Pathology and Laboratory Medicine, Health Science Division, Loyola University Chicago, Chicago, IL. ²Dow University of Health Science, Karachi. ³Department of Microbiology, University of Karachi, Karachi. ⁴Dow Fly Lab and Stock Center, Dow College of Biotechnology, Dow University of Health Sciences, Karachi

11:18

THROMBOPHILIA TESTING IN PATIENTS WITH CRYPTOGENIC STROKE
MEERA SRIDHARAN, EUGENE SCHARF, ANEEL ASHRANI, ANIMESH PARDANANI, RAJIV PRUTHI. Mayo Clinic, Rochester, MN, USA

SHORT TALKS - INTEGRATING GENETICS, IMMUNOLOGY, AND DIAGNOSTICS IN MODERN COAGULATION MEDICINE / FROM GENETIC VARIANTS TO CLINICAL PATHWAYS: EVOLVING INSIGHTS IN BLEEDING AND THROMBOTIC DISORDERS
Chair/Organizer: Dawn Rotellini, Tomasz Kaminski
Oregon Ballroom 204

10:30

NEUTROPHIL-DEPENDENT INTERFERONOPATHY PROMOTES JOINT DAMAGE IN HEMOPHILIA.
TOMASZ KAMINSKI¹, NICHOLAS SWENDROWSKI¹, MARGARET V. RAGNI², LYNN MALEC^{1, 3}, PRITHU SUNDD^{1, 4}. ¹Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI, USA. ²Department of Medicine, Division of Hematology, University of Pittsburgh, Pittsburgh, WI, USA. ³Departments of Medicine and Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. ⁴Department of Medicine (Hematology and Oncology), Medical College of Wisconsin, Milwaukee, WI, USA

10:42

THE MEXICAN AMERICAN RESTRICTED ARG500LEU F2 VARIANT PROTHROMBIN-RGV ENCODES THE ZYMOGEN OF AN ANTITHROMBIN-SENSITIVE HYPOCOAGULABLE THROMBIN THAT LIKELY PROTECTS AGAINST VENOUS THROMBOEMBOLISM (VTE)
HENRY J. MEAD¹, VINCENT P. DIEGO^{2, 3}, MARCIO A. ALMEIDA^{2, 3}, LUIS PENA MARQUEZ², AFSHIN AMERI⁴, JUAN M. PERALTA^{2, 3}, LAURA ALMASY¹¹, HARALD H. GORING^{2, 3}, MICHAEL RECHT^{5, 6}, JOANNE E. CURRAN^{2, 3}, KEVIN R. VIEL³, MIGUEL A. ESCOBAR^{7, 8}, TAMMUELLA CHRISENTERY-SINGLETON^{9, 10}, SARAH WILLIAMS-BLANGERO^{2, 3}, JOHN BLANGERO^{2, 3}, TOM E. HOWARD^{2, 3}. ¹Haplogenics, Brownsville, TX, USA. ²South Texas Diabetes and Obesity Institute and Department of Human Genetics, College of Sciences, Brownsville, TX, USA. ³Histonis, Portsmouth, NH, USA. ⁴Department of Pediatrics, Division of Hematology and Oncology, Georgia Health Sciences University, Augusta, GA, USA. ⁵Yale Center for bleeding and Clotting disorders, New Haven, CT, USA. ⁶, Yale University School of Medicine, New Haven, CT, USA. ⁷Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, Houston, TX, USA. ⁸Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA. ⁹American Thrombosis a Hemostasis Network, Hickory, NC, USA. ¹⁰Ochsner Clinic Foundation, New Orleans, LA, USA. ¹¹Department of Biomedical and Health Informatics, Lifespan Brain Institute, Philadelphia, PA, USA

10:54

FACTOR VIII INHIBITOR KINETICS AND REAGENT COMPOSITION UNDERLIE FALSE-POSITIVE LUPUS ANTICOAGULANT PATTERNS IN ACQUIRED HEMOPHILIA A
HAMISH NICOLSON^{1, 2}, STEVEN WONG^{1, 2}. ¹Providence Health Care, St. Paula, Vancouver, BC, Canada. ²Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

11:06

INCREASING THE TIMELINESS OF SURGERY PLANDOCUMENTATION FOR PATIENTS WITH BLEEDING DISORDER-A QUALITY IMPROVEMENT PROJECT (THSNATRAVEL AWARDEE)
AMBER PRUETT¹, VILMARIE RODRIGUEZ^{1, 2}, CHARMAINE BIEGA¹, MICHELLE HALLAM¹, COURTNEY KIRBY¹, OLIVIA LAHOTE¹, SARAH H O'BRIEN^{1, 2}, LYNDA VILLA-GOMEZ^{1, 2}, AMY L. DUNN^{1, 2}. ¹Nationwide Children's Hospital Division of Pediatric Hematology, Oncology, Bone Marrow Transplant and Apheresis, Columbus, OH, USA. ²The Ohio State University College of Medicine, Columbus, OH, USA

11:45 - 12:45 PM

SATELLITE SYMPOSIUM

EXPLORING A SUBCUTANEOUS TREATMENT OPTION IN HEMOPHILIA CARE WITH HYMPAVZI (MARSTACIMAB-HNCQ) (SPONSORED BY PFIZER, INC. )
B115-116

Session will include a presentation on HYMPAVZI (marstacimab-hncq): the mechanism of action, key clinical trial data, administration guidelines, and patient cases followed by an audience Q&A. Speaker: Dr. Craig Kessler

GENE THERAPY IN HEMOPHILIA B: A JOURNEY OF INNOVATION AND IMPACT (SPONSORED BY CSL)
B113-114

Gene Therapy in Hemophilia B: A Journey of Innovation and Impact is a dynamic symposium hosted by leading hematology experts to investigate the evolution of gene therapy in hemophilia B, review five-year durability data from the HOPE-B trial, and share real-world clinical insights. This interactive session will also highlight a powerful patient story that brings the promise of gene therapy to life. This symposium provides an opportunity to deepen your understanding of transformative treatment approaches and explore considerations for the future for gene therapy in hemophilia B.

REAL-WORLD MANAGEMENT OF HEMOPHILIA A AND B: CLINICAL CASES WITH REBALANCING AND FACTOR REPLACEMENT THERAPIES (SPONSORED BY SANOFI)
B110-112

Join an interactive, poster-style session where leading experts present real-world patient cases managed with Sanofis portfolio of therapies for hemophilia A and B. Learn how personalized treatment strategies are applied in clinical practice from your peers.

12:45 - 1:30 PM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Exhibit Hall A

A1. ANTICOAGULATION CLINICS

200

IMPORTANCE OF ANTICOAGULATION CLINICS IN IDENTIFICATION OF ANTIPHOSPHOLIPID ANTIBODY SYNDROME MISCLASSIFICATION
DEBORAH GILLARD¹, LISA BAUMANN KREUZIGER^{1, 2, 3}, JENNIFER HARDMAN¹. ¹Froedtert Health, Milwaukee, WI, USA. ²Medical College of Wisconsin, Milwaukee, WI, USA. ³Versiti Blood Research Institute, Milwaukee, WI, USA

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

201

A RETROSPECTIVE US CLAIMS DATABASE STUDY ASSESSING TREATMENT PATTERNS AND BLEEDING EPISODES IN PATIENTS WITH PREVIOUSLY TREATED PRIMARY IMMUNE THROMBOCYTOPENIA
JOAO DA SILVA¹, YU-CHEN YEH², FIRAS DABBOUS³, CARLOS E BERTAGLIA GONCALVES⁴, SARAH HALE⁴, QIAN LI³, MEI LU⁴, SEAN SANA², DOROTHY ROMANUS². ¹Thermo Fisher Scientific, Azores, Portugal. ²Takeda Development Center Americas, Inc, Cambridge, MA, USA. ³Thermo Fisher Scientific, Bethesda, MD, USA. ⁴Takeda Pharmaceuticals U. S. A, Inc, Lexington, MA, USA

202

HEPARIN INDUCED THROMBOCYTOPENIA IN ORTHOPEDIC SURGERY PATIENTS - A NATIONAL INPATIENTS SAMPLE DATABASE STUDY
SRUTHI/P RAMANAN¹, KALAIVANI BABU², SRINISHANT RAJARAJAN², YIN YUE³, DEEP SHAH¹. ¹AHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. ²Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA, USA. ³Allegheny Health Network, Pittsburgh, PA, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

203

TYPE 2N VON WILLEBRAND DISEASE IN PREGNANCY AND POSTPARTUM: A CASE REPORT
LAUREN N DURAND, ROBERT BONA. Yale University Dept of Medicine and Pediatrics, New Haven, CT, USA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

205

ASSAY PERFORMANCE AND HEAT-INACTIVATION CHALLENGES OF EFANESOCTOCOG ALFA IN FACTOR VIII ACTIVITY AND INHIBITOR TESTING
ERIN L AAKRE, MELISSA S STUART, JULIE I TANGE, JULIANA PEREZ BOTERO, RAJIV K PRUTHI. Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA

206

MAJOR ORTHOPEDIC SURGERIES CONDUCTED UNDER FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A AND B, WITH AND WITHOUT INHIBITORS
LARISSA BORNIKOVA¹, LAURENT FRENZEL², KAAN KAVAKLI³, LAISZLA&SUP3; NEMES⁴, STEPHANIE P'NG⁵, JING SUN⁶, CHUR-WOO YOU⁷, EZIO ZANON⁸, VANESSA SALINAS⁹, LAUREL A. MENAPACE¹⁰, SALIM KICHOU¹¹, ABHIMANYU YARRAMANENI¹⁰, YUQIAN SHEN¹⁰, ALOK SRIVASTAVA¹². ¹Cancer Center, Massachusetts General Hospital, Boston, MA, USA. ²Groupe Hospitalier Necker Enfants Malades, Paris, France. ³Ege University Faculty of Medicine, Izmir, Turkey. ⁴Central Hospital of Northern Pest a, Budapest, Hungary. ⁵Fiona Stanley Hospital, Murdoch, Australia. ⁶Nanfang Hospital, Guangzhou, China. ⁷Eulji University Hospital, Daejeon, South Korea. ⁸Azienda Ospedale UniversitAn di Padova, Padua, Italy. ⁹Center for Inherited Blood, Disorders, Orange, CA, USA. ¹⁰Sanofi, Cambridge, MA, USA. ¹¹Sanofi Genzyme, Paris, France. ¹²St. John's Medical College Hospital, Bengaluru, India

207

LIMITATION OF AUTOMATED VON WILLEBRAND TESTING IN IDENTIFYING A CASE OF ACQUIRED VON WILLEBRAND SYNDROME
SHANNON GOODALL, MAISSAA JANBAIN. Section of Hematology and Medical Oncology, Tulane School of Medicine, New Orleans, LA, USA

209

INCREASED LEVELS OF D-DIMER AND PLASMINOGEN ACTIVATOR INHIBITOR-1 IN IMMUNE THROMBOCYTOPENIA: IMPLICATIONS FOR THROMBOTIC COMPLICATIONS
KANNAN MEGANATHAN¹, JEEVANATHAM. KAVIARASI¹, CHITRALI L ROY¹, RAVI RANJAN², MANORANJAN MAHAPATRA², RENU SAXENA², JAWED FAREED³. ¹Blood and Vascular Biology Research Lab, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur 610101. INDIA, Thiruvarur, India. ²Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029. INDIA, New Delhi, India. ³Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago IL 60153, USA, Chicago, IL, USA

211

INVESTIGATING THE EFFECT OF POPULATION PHARMACOKINETIC-GUIDED PDVWF/FVIII (1:1) PROPHYLAXIS FOR SEVERE VWD IN A REAL-WORLD SETTING: THE POPPK-WILPROPHY STUDY
ROBERT F. SIDONIO, JR. ¹, RON A. A. MATHAAT². ¹Professor of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. ²Department of Hospital Pharmacy a Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

212

EVALUATING THE SAFETY AND TOLERABILITY OF SWITCHING FROM EMICIZUMAB TO FITUSIRAN PROPHYLAXIS IN MALES AGED &GE;12 YEARS WITH SEVERE HEMOPHILIA A, WITH AND WITHOUT INHIBITORS: SWITCH STUDY
GUY YOUNG¹, EKTA S CHHABRA², SHARIQ ALI², LILA-SABRINA FETITA³, MAREK DEMISSIE², ABHIMANYU YARRAMANENI², CHANCHALA KADDI², SHENG C CHOU⁴. ¹Childrena, Los Angeles, CA, USA. ²Sanofi, Cambridge, MA, USA. ³Sanofi Genzyme, Paris, France. ⁴Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

A7. PATHOPHYSIOLOGY OF THROMBOSIS

213

EVALUATION OF BOVINE MUCOSAL HEPARINS USING PLASMA-BASED AND WHOLE BLOOD CLOTTING ASSAYS
TROY LABORE, BRENT CUDAL, MONICA PASTORIOUS, DEBRA HOPPENSTEADT, JAWED FAREED, WALTER JESKE, JEANINE WALENGA. Loyola University Chicago Department of Pathology and Laboratory Medicine, Chicago, IL, USA

A8. ANTITHROMBOTIC THERAPY

215

RETHINKING EXTENDED ANTICOAGULATION IN CANCER: IS LESS MORE? A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS
URSULA MEDEIROS ARAUJO DE MATOS¹, EDUARDO DAN ITAYA¹, MOANA DIVINA DA SILVA SANTIAGO¹, PATRICK FROELICH MELDOLA², PEDRO L LAGE BODOUR DANIELIAN³, GUSTAVO J SILVA SANCHEZ¹, SWARUP KUMAR⁴, RITIKA VANKINA⁴. ¹Internal Medicine Department, University of Connecticut, Farmington, CT, USA. ²Federal University of Santa Catarina, School of Medicine, Santa Catarina, Brazil. ³Harvard T. H. Chan School of Public Health, Boston, MA, USA. ⁴Hematology and Oncology Department, University of Connecticut, Farmington, CT, USA

216

RISK FACTORS FOR SUPRATHERAPEUTIC APTTS ON HEPARIN INTRAVENOUS INFUSION
WADE TUNG, KATELYN SYLVESTER, KAITLIN CROWLEY, DAREEN KANAAN. Brigham and Women's Hospital, Boston, MA, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

217

EVALUATION OF UPDATED PROTOCOL FOR INTRAOPERATIVE ANTITHROMBIN-III AND UNFRACTIONATED HEPARIN ADMINISTRATION DURING CARDIAC SURGERY
RAZAN FANNOUN, STEPHANIE DAVIS, KATIE DANE, JOHN LINDSLEY, MARGARET BUCK, JESSICA CROW, PROMISE ARIYO. The Johns Hopkins Hospital, Baltimore, MD, USA

218

EVALUATION OF ANTITHROMBIN III UTILIZATION IN CARDIOVASCULAR SURGERY REQUIRING CARDIOPULMONARY BYPASS&MDASH;A RETROSPECTIVE REVIEW OF INSTITUTIONAL PRACTICE
EKATERINA PECHENKO¹, JEN OSBORN¹, JOSH BREEDING², VRUSHALI PACHPANDE¹. ¹M Health Fairview University of Minnesota Medical Center, Minneapolis, MN, USA. ²M Health Fairview Southdale Hospital, Edina, MN, USA

219

IMPLEMENTATION AND OUTCOMES OF A PHARMACIST-DRIVEN PROTOCOL FOR DIRECT THROMBIN INHIBITOR TITRATION IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA
AMBER L WOOLLEY, ANNE E ROSE. UW Health, Madison, WI, USA

1:30 - 3:00 PM

THROMBOSIS / LABORATORY

AUTOIMMUNE THROMBOSIS SYNDROMES
Chair/Organizer: Sabrina Racine-Brzostek, Leonardo Brandao
Oregon Ballroom 204

1:30

PF4 DISORDERS INCLUDING PEDIATRIC ISSUES
TED WARKENTIN.

2:00

IBD AND THROMBOSIS
ERIC BENCHIMOL.

2:30

ANTICOAGULANT MONITORING IN PATIENTS WITH APS--PRACTICAL CASE-BASED EXAMPLES
ANDY GOODWIN.

1:30 - 3:00 PM

BASIC SCIENCE

COAGULATION AT THE INTERSECTION OF INFLAMMATION AND INFECTION
Chair/Organizer: Bryce Kerlin, Kandace Gollomp
Oregon Ballroom 201

1:30

VWF & PLATELET REACTIVITY WITH INFLAMMATION AND INFECTION (DENGUE)
MARTHA EVA VIVEROS.

2:00

TRIAD OF PLATELETS, NETS, AND SEPSIS
KANDACE GOLLOMP.

2:30

INTERACTION OF PLATELETS AND VIRUSES
ED PRYZDIAL.

1:30 - 3:00 PM

HEMOSTASIS

LET'S GET THIS IRONED OUT (IMPACT OF UNTREATED BLEEDING IN WOMEN/GIRLS WITH BLEEDING DISORDERS)
Chair/Organizer: Julie Jaffray, Bethany Samuelson Bannow
Oregon Ballroom 203

1:30

IMPACT OF IRON DEFICIENCY AND ANEMIA
GLAIVY BATSULI.

2:00

APPROACHES TO TREATING WOMEN & GIRLS WITH BLEEDING DISORDERS
JULIE JAFFRAY.

2:30

THE DATA VACCUUM: WOMEN NOT INCLUDED IN CLINICAL TRIALS MEANS WE DON'T KNOW HOW THEIR HORMONES AFFECT CURRENT TREATMENTS FOR BLEEDING, WHAT IS MOST EFFICACIOUS FOR TYPES OF BLEEDING
DAWN ROTELLINI.

3:00 - 3:45 PM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Exhibit Hall A

A1. ANTICOAGULATION CLINICS

300

ANTICOAGULATION STEWARDSHIP IN THE REAL-WORLD SETTING
NGHI HA, DENISE SUTTER-LONG, ANISA BICI, ERIN MOULAND, ELIZABETH RENNER. Michigan Medicine, Ann Arbor, MI, USA

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

301

MODIFIED DURABLE PLATELET RESPONSE BY INTERNATIONAL WORKING GROUP CRITERIA: LUNA3 PHASE 3 STUDY OF RILZABRUTINIB VS PLACEBO IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
WALEED GHANIMA¹, YOSHITAKA MIYAKAWA², NICHOLA COOPER³, MARIE LUISE HA&FRAC14;TTER-KRAPNKE⁴, MARIA CRISTINA PASCUAL IZQUIERDO⁵, SYLVAIN AUDIA⁶, MEREDITH C. FOSTER⁷, MARIA BELEN RODRIGUEZ⁷, JING ZHAO⁷, AHMED DAAK⁷, DAVID J. KUTER⁸, DAVID FARBER⁷. ¹A, Oslo, Norway. ²Department of Hematology, Saitama Medical University, Saitama, Japan. ³Hammersmith Hospital, London, United Kingdom. ⁴Department of Hematology, Oncology and Tumorimmunology, CharitAc - UniversitActsmedizin Berlin, Freie UniversitAct Berlin and Humboldt UniversitAct zu Berlin, Berlin, Germany. ⁵Department of Hematology, Gregorio MaraApon Hospital, Madrid, Spain. ⁶CHU Dijon Bourgogne - Hopital Francois Mitterrand, Dijon, France. ⁷Sanofi, Cambridge, MA, USA. ⁸Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

302

IDENTIFICATION OF A PROPOSED NOVEL PATHOGENIC MYH-9 MUTATION IN A FAMILY WITH DUAL DIAGNOSIS OF VON WILLEBRAND DISEASE AND SUSPECTED MYH9-RELATED DISEASE
KAWANA SIMON¹, RADHA VYAS¹, COLLEEN CICCOSANTI². ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. ²Division of Hematology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

303

VALIDATION OF THE FIIX ASSAY ON WERFEN ACL TOP 750 ANALYZER
A ESHAGHPOUR¹, K MOFFAT^{1, 2}, S CARLINO², L LETERTRE³, E BELLEY-COTE¹, D. M WITT⁴, B GUDMUNDSDOTTIR³, P ONUNDARSON^{3, 5}, M CROWTHER¹. ¹Department of Medicine, McMaster University, Hamilton, ON, Canada. ²Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada. ³Departments of Medicine and Laboratory Medicine, Landspitali National University of Iceland, Reykjavik, Iceland. ⁴University of Utah College of Pharmacy, Salt Lake City, UT, USA. ⁵Faculty of Medicine, University of Iceland, Reyjkavik, Iceland

304

PERIOPERATIVE HEMOSTATIC STRATEGIES IN TOTAL KNEE ARTHROPLASTY FOR HEMOPHILIA: A SYSTEMATIC EVIDENCE REVIEW OF BLEEDING, FACTOR USE, AND THROMBOTIC RISK
JACK RUSSEK¹, ANGAD THAKRAL². ¹Touro University California, Vallejo, CA, USA. ²Touro University California, Vallejo, CA, USA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

305

MAJOR DENTAL SURGERIES CONDUCTED UNDER FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A AND B, WITH AND WITHOUT INHIBITORS
SUCHITRA S ACHARYA¹, LAURENT FRENZEL², KAAN KAVAKLI³, TEH-LIANE KHOO⁴, LAISZLA&SUP3; NEMES⁵, JING SUN⁶, TE-FU WENG⁷, CHUR-WOO YOU⁸, SALIM KICHOU⁹, ABHIMANYU YARRAMANENI¹⁰, LAUREL A MENAPACE¹⁰, YUQIAN SHEN¹⁰, EZIO ZANON¹¹. ¹Northwell Health, New York, NY, USA. ²Groupe Hospitalier Necker Enfants Malades, Paris, France. ³Ege University Faculty of Medicine, Izmir, Turkey. ⁴Royal Prince Alfred Hospital, Sydney, Australia. ⁵Central Hospital of Northern Pest a, Budapest, Hungary. ⁶Nanfang Hospital, Guangzhou, China. ⁷Chung Shan Medical University Hospital, Taichung, Taiwan. ⁸Eulji University Hospital, Daejeon, South Korea. ⁹Sanofi Genzyme, Paris, France. ¹⁰Sanofi, Cambridge, MA, USA. ¹¹Azienda Ospedale UniversitAn di Padova, Padua, Italy

306

CONCIZUMAB EFFICACY IN PATIENTS WITH HEMOPHILIA A/B WITHOUT INHIBITORS FROM THE PHASE 3 EXPLORER8 STUDY: A POST-HOC SENSITIVITY ANALYSIS FOR THE INTRA-PATIENT COMPARISON OF CONCIZUMAB WITH PREVIOUS PROPHYLAXIS
ANTHONY KC CHAN¹, HERMANN EICHLER², JULIEN BOVET³, RENACE BROWN FRANDSEN³, ALLISON P WHEELER⁴, EMILY WATERS⁵, PRATIMA CHOWDARY⁶, LEANDRA LEPORTE⁵. ¹Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada. ²Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg, Germany. ³Novo Nordisk A/S, SAcborg, Denmark. ⁴Division of Pediatric Hematology/Oncology a Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA, USA. ⁵Novo Nordisk Inc, Plainsboro, NJ, USA. ⁶Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, and Department of Haematology, Cancer Institute, University College London, London, United Kingdom

307

COMBINED FACTOR V AND FACTOR VIII DEFICIENCY ASSOCIATED WITH COMPOUND HETEROZYGOUS LMAN1 VARIANTS: A CASE REPORT
RIDA HAIDER ^{1, 2}, NATALIE MONTANEZ^{1, 3}, JOANNA LARSON^{1, 3}, HARISH ESWARAN^{1, 4}, MIGUEL ESCOBAR^{1, 4}. ¹Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA. ²University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Medical Genetics, Houston, TX, USA. ³University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Hematology, Houston, TX, USA. ⁴University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics and Internal Medicine, Division of Hematology, Houston, TX, USA

308

UPDATE ON A NOVEL INVESTIGATIONAL ADENO-ASSOCIATED VIRUS GENE THERAPY, SPK-8011QQ: RATIONALE AND DESIGN OF A PHASE IIB TRIAL
ANDREW D. LEAVITT¹, ALICE COHEN², M. ELAINE EYSTER³, KRISTINA HALEY⁴, AKSHAT JAIN⁵, DANIEL J. LEE⁶, MADDALENA MARCHESI⁷, CATHERINE MCGUINN⁸, NICOLAS RECEVEUR⁷, MICHAEL RECHT ⁹, AMIT SONI ¹⁰, SASHA SRECKOVIC¹¹, MILES VILJANEN¹¹. ¹Departments of Medicine and of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA. ²Newark Beth Israel Medical Center, Newark, NJ, USA. ³Penn State Hershey Medical Center, Hershey, PA, USA. ⁴Hemostasis and Thrombosis Center, Oregon Health and Science University, Portland, OR, USA. ⁵Department of Pediatrics, Division of Hematology/Oncology, Loma Linda University School of Medicine, Loma Linda, CA, USA. ⁶Department of Hematology/Oncology, Kaiser Permanente, Vallejo/Vacaville, CA, USA. ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland. ⁸Department of Pediatrics, Weill Cornell Medicine College, New York, NY, USA. ⁹Hemophilia Treatment Center and Pediatric Hematology-Oncology, Yale University School of Medicine, New Haven, CT, USA. ¹⁰Center for Inherited Blood Disorders, Orange, CA, USA. ¹¹Genentech, Inc, South San Francisco, CA, USA

309

APOLD1-ASSOCIATED VASCULAR-TYPE BLEEDING DISORDER PRESENTING WITH SEVERE POSTOPERATIVE HEMORRHAGE: A CASE REPORT
NATALIE MONTANEZ ^{1, 2}, RIDA HAIDER ^{1, 3}, JOANNA LARSON^{1, 2}, HARISH ESWARAN^{1, 4}, MIGUEL ESCOBAR^{1, 4}. ¹Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA. ²University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Hematology, Houston, TX, USA. ³University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Division of Medical Genetics, Houston, TX, USA. ⁴University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics and Internal Medicine, Division of Hematology, Houston, TX, USA

310

SIXTH INTERIM ANALYSIS OF THE HEM-POWR STUDY: EVALUATING REAL-WORLD EFFECTIVENESS AND SAFETY OF DAMOCTOCOG ALFA PEGOL IN PATIENTS WITH SEVERE AND NONSEVERE HEMOPHILIA A IN THE UNITED STATES
MARK T REDING¹, BENG FUH², VANESSA SALINAS³, MAISSAA JANBAIN⁴. ¹Center for Bleeding and Clotting Disorders, University of Minnesota, Minneapolis, MN, USA. ²East Carolina University, Greenville, NC, USA. ³Center for Inherited Blood Disorders, Orange, CA, USA. ⁴Tulane School of Medicine, New Orleans, LA, USA

311

BILIARY EVENTS IN THE FITUSIRAN CLINICAL DEVELOPMENT PROGRAM WITH THE ANTITHROMBIN-BASED DOSE REGIMEN
MINDY SIMPSON¹, CANAN ALBAYRAK², SAVITA RANGARAJAN^{3, 4}, OLEKSANDRA STASYSHYN⁵, JING SUN⁶, CHUR-WOO YOU⁷, ABHIMANYU YARRAMANENI⁸, LAUREL A. MENAPACE⁸, YUQIAN SHEN⁸, KAAN KAVAKLI⁹. ¹Rush Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA. ²Ondokuz Mayis University Faculty of Medicine, Department of Pediatric Hematology, Samsun, Turkey. ³Advanced Centre for Oncology, Haematology and Rare Diseases, K. J. Somaiya Super Specialty Hospital, Mumbai, India. ⁴Faculty of Medicine, University of Southampton, Southampton, United Kingdom. ⁵Institute of Blood Pathology and Transfusion Medicine, Lviv. ⁶Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. ⁷Department of Pediatrics, Eulji University School of Medicine, Seoul, Korea. ⁸Sanofi, Cambridge, MA. ⁹Division of Hematology, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey

312

THE ROLE OF VON WILLEBRAND FACTOR IN SICKLE CELL DISEASE CHRONIC ORGAN DAMAGE
MARTA WOLOSOWICZ¹, TOMASZ KAMINSKI¹, AYYANAR SIVANANTHAM¹, NICHOLAS SWENDROWSKI¹, NANDHINE RAJASEKHAR¹, TIRTHADIPA PRADHAN-SUNDD^{1, 2}. ¹Versiti Blood Research Institute, Milwaukee, WI, USA. ²Medical College of Wisconsin, Wauwatosa, WI, USA

A7. PATHOPHYSIOLOGY OF THROMBOSIS

313

MOBILE PATIENTS MISS AND REFUSE MORE DOSES OF VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS
BRANDYN D. LAU^{1, 2, 3, 4}, ERIK H. HOYER^{1, 2}, DAURYNE L. SHAFFER⁵, PEGGY S. KRAUS⁵, ELLIOTT R. HAUT^{1, 2, 3, 4}, MICHAEL B. STREIFF^{1, 2}. ¹Johns Hopkins School of Medicine, Baltimore, MD, USA. ²Armstrong Institute for Patient Safety and Quality, Baltimore, MD, USA. ³Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA. ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ⁵Johns Hopkins Hospital, Baltimore, MD, USA

A8. ANTITHROMBOTIC THERAPY

314

LOW RISK FOR MENINGOCOCCAL INFECTIONS WITH SYSTEMICALLY ADMINISTERED PEGCETACOPLAN, A COMPLEMENT C3 AND C3B INHIBITOR
CARLOS DE CASTRO¹, SHEENA PATEL², HOLLY SNYDER³, PETER HILLMEN³. ¹Duke University, Durham, NC, USA. ²Swedish Orphan Biovitrum AB, Stockholm, Sweden. ³Apellis Pharmaceuticals, Inc, Waltham, MA, USA

315

APIXABAN VS RIVAROXABAN FOR VENOUS THROMBOEMBOLISM IN GASTROINTESTINAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
URSULA MEDEIROS ARAUJO DE MATOS¹, PEDRO LUIZ LAGE BODOUR DANIELIAN², MOANA DIVINA DA SILVA SANTIAGO¹, NICOLE SEQUEIRA¹. ¹Internal Medicine Department, University of Connecticut, Farmington, CT, USA. ²Harvard T. H. Chan School of Public Health, Boston, MA, USA

316

MANAGEMENT AND OUTCOMES OF SUBTHERAPEUTIC WARFARIN ANTICOAGULATION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND MECHANICAL MITRAL VALVES
SARA R VAZQUEZ^{1, 2}, STEPHEN SHORT², SPENCER GILBERT^{1, 2}, DANIEL M WITT^{1, 2}. ¹University of Utah Health Thrombosis Service, Murray, UT, USA. ²University of Utah College of Pharmacy, Salt Lake City, UT, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

317

HEALTHCARE RESOURCE UTILIZATION IN PEOPLE WITH HEMOPHILIA TREATED WITHIN VS. EXTERNAL TO U. S. HEMOPHILIA TREATMENT CENTER NETWORK CLINICS: AN UPDATE FROM THE CHESS US STUDY
ENRICO FERRI GRAZZI¹, MING LIM², NICOLE CROOK³, MARIA SANTAELLA⁴, MICHAEL RECHT^{4, 5}, ADAM GIERMASZ⁶, JONATHAN ROBERTS⁷, RANDALL CURTIS⁸. ¹Federation of Hemophilia Associations (FedEmo), Milan, Italy. ²University of Utah, Salt Lake City, UT, USA. ³Center for Inherited Blood Disorders, Orange, CA, USA. ⁴National Bleeding Disorders Foundation, New York, NY, USA. ⁵Yale School of Medicine, New Haven, CT, USA. ⁶University of California, Davis, CA, USA. ⁷Bleeding a Clotting Disorders Institute, Peoria, IL, USA. ⁸Factor VIII Computing, Walnut Creek, CA, USA

318

HIGH STAKES HEMOSTASIS: DESCRIBING RISKS OF TRIPLE ANTITHROMBOTIC THERAPY IN PATIENTS ON TEMPORARY MECHANICAL CIRCULATORY SUPPORT
JOHN PURDIE, ERIC B. SIMPSON, ZACHARY R. SMITH, MIR B. BASIR, KRISTIN GRIEBE, BENJAMIN A. AUGUST. Henry Ford Hospital, Detroit, MI, USA

3:00 - 4:00 PM

POSTER SESSION

VIRTUAL POSTERS
Virtual Platform

ADEQUACY OF STANDARD THERAPEUTIC LOWMOLECULAR-WEIGHT HEPARIN DOSING IN PREGNANT WOMEN WITH PROSTHETIC HEART VALVES: AN ANTI-FACTOR XABASED EVALUATION (THSNATRAVEL AWARDEE)
TUSHAR SEHGAL¹, K. APARNA SHARMA², AMBUJ ROY³. ¹Department of Laboratory Medicine, Delhi, India. ²Department of Obstetrics and Gynaecology, Delhi, India. ³Department of Cardiology, Delhi, India

DRUG-INDUCED THROMBOCYTOPENIA FROM PROTON PUMP INHIBITORS AND H BLOCKERS: A SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS OF PUBLISHED CASE REPORTS
SWAPNIL SURPUR, HIMANI MONGIA, SAMEER BHIMANI, MOHAMED AHMED, TEODOR LAZIC, JAMES CORTESE. The Wright Center for GME, Scranton, PA, USA

OPTIMIZING ANTICOAGULANT STRATEGIES IN PREGNANCY-ASSOCIATED HIT AND ACUTE STROKE IN A REAL-WORLD COMMUNITY SETTING
PEDROM FARID^{1, 2, 3}, MARCO A HERRERA QUIJANO^{1, 2, 3}, OMAR SAMARRAIE², ANDREA CERVI^{1, 2, 3}. ¹Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. ²University of Windsor, Windsor, ON, Canada. ³Windsor Regional Hospital, Windsor, ON, Canada

TRENDS IN AGE-ADJUSTED MORTALITY RATES FOR DISSEMINATED INTRAVASCULAR COAGULATION IN SOLID AND HEMATOLOGIC CANCER PATIENTS: A 22-YEAR ANALYSIS OF UNITED STATES MORTALITY DATA BY SEX, RACE, AND GEOGRAPHIC REGION, 1999-2020.
JISS JOY¹, RAHUL ANAND¹, JOAN D. BECKMAN². ¹Department of Internal Medicine, The Guthrie Clinic, Robert Packer Hospital, Sayre, PA, USA. ²Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA

COMPARATIVE ANALYSIS OF CANCER-INDUCED VENOUS THROMBOEMBOLISM PREDICATORS AND RISK ASSESSMENT MODELS: A SYSTEMATIC REVIEW
TAREK A. ISSA¹, NOOR A. HAYKAL¹, YASMIN M. ELSAYED¹, ISLAM A. ELJILANY², HAZEM F. ELEWA¹. ¹College of Pharmacy, QU Health, Qatar University, Doha, Qatar. ²H. a, Tampa, FL, USA

COULD ELEVATED HOMOCYSTEINE BE A RISK FACTOR FOR CEREBRAL VENOUS THROMBOSIS?
NAWRIS ALHASSAN¹, JAGDISH LAL², SUSMIN KARKI³. ¹Hope Clinic, Midvale, UT, USA. ²Burnaby Chronic Pain a Rehabilitation Clinic, Burnaby, BC, Canada. ³Institute of Medicine, Tribhuvan University, Maharajgunj, Nepal

VENOUS THROMBOEMBOLISM IN INTERNAL MEDICINE INPATIENTS: A ONE-YEAR PILOT STUDY OF PREVALENCE, PATIENT CHARACTERISTICS, AND SURVIVAL OUTCOMES FROM TURKEY.
BULENT KANTARCIOGLU^{1, 3}, SULTAN GOZDE TEMIZ², AYSE NILGUN KUL¹, JAWED FAREED³, GULBUZ SEZGIN². ¹University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Department of Internal Medicine, Division of Hematology, Istanbul, Turkey. ²University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey. ³Loyola University Chicago, Department of Pathology a Laboratory Medicine, Cardiovascular Research Institute, Health Science Division, Maywood, IL, USA

DIAGNOSTIC PERFORMANCE OF THE KHORANA, ONKOTEV, AND PROTECHT SCORES FOR PREDICTING VENOUS THROMBOEMBOLISM IN OVARIAN CANCER
EMILIE MATHESON¹, WESLEY CHORNEY¹, RAHUL SINGH¹, SUSAN O'SHEA^{1, 2}. ¹University College Cork, Cork, Ireland. ²Bons Secours Hospital, Cork, Ireland

INTERVENTIONAL THROMBOLYSIS VS ANTICOAGULATION ALONE FOR MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED ACUTE VENOUS THROMBOEMBOLISM: A REAL-WORLD PROPENSITY-MATCHED ANALYSIS
HASSAAN J. ABBASI¹, DEVI PREETHAM R. VEERAMAGRI¹, YASHAR HAGHIGHI¹, PATRICK J. WILLARD², CHRISTOPHER W. BAILEY³. ¹Virginia Commonwealth University School of Medicine, Richmond, VA, USA. ²Department of Hematology-Oncology, VCU Health, Richmond, VA, USA. ³Division of Vascular Interventional Radiology, VCU Health, Richmond, VA, USA

TO CLOT OR NOT - RISK OF HOSPITAL-ACQUIRED VENOUS THROMBOEMBOLISM IN PATIENTS PRESCRIBED ASPIRIN AFTER TOTAL HIP ARTHROPLASTY/TOTAL KNEE ARTHROPLASTY
AMY N. CRUZ¹, JOSH ROBERTS¹, JEREMIAH DUBY¹, JAMES CHHEN¹, MICHELLE KRICHEVSKY², TIFFANY PON^{1, 2}. ¹University of California Davis, Sacramento, CA, USA. ²University of California San Francisco, San Francisco, CA, USA

NOVEL THERAPEUTIC LIMITS CHRONIC INFLAMMATION IN ANIMAL MODELS OF CHRONIC INFLAMMATION.
P IVERSEN¹, P KEMPAIAH², G DORN², E CAMPBELL², Z KAKABADZE³, E RAMACCIOTTI⁴, J FAREED². ¹. Oregon State University, Corvallis, OR, USA. ²Loyola University Medical Center, Maywood, IL, USA. ³Tbilisi State Medical University, Tbilisi, Georgia. ⁴Science Valley Research Institute, Sao Paulo, Brazil

PARADOXICAL APIXABAN ANTI-XA LEVELS AFTER ANDEXANET ALFA: A CASE REPORT ON UNRELIABLE LABORATORY MONITORING AND EARLY THROMBOTIC RISK
SEAN TWARDY¹, FARZEEN SYED², SHELLEY KALSI². ¹Uniformed Services University of the Health Sciences, Bethesda, MD, USA. ²National Institutes of Health, Bethesda, MD, USA

IMPLEMENTING A STRUCTURED, MULTIDISCIPLINARY HOME INFUSION EDUCATION PROGRAM FOR PEDIATRIC BLEEDING DISORDERS
JULIE BASCONES, BRANDEN BERIA, AIMEE FOORD. Cure 4 the Kids Foundation, Las Vegas, NV, USA

IS PSEUDOTHROMBOCYTOPENIA ONLY A LABORATORY IN VITRO PHENOMENON?
MARIKA PIKTA^{1, 2}, LAURA JOHANNA METTIS^{3, 4}, MARIA KEERNIK⁵, KRISTI LEPIK⁶, KADRI SAKS⁶. ¹Department of Laboratory Medicine, North Estonia Medical Centre, Tallinn, Estonia. ²Department of Health Technologies, Tallinn University of Technology, Tallinn, Estonia. ³Hematology Department, North Estonia Medical Centre, Tallinn, Estonia. ⁴University of Helsinki, Helsinki, Finland. ⁵Department of Laboratory Genetics, University of Tartu, Tartu, Estonia. ⁶Haematology Department, Tallinn Children`s Hospital, Tallinn, Estonia

DIAGNOSTIC LIMITATION OF MIXING STUDIES IN COAGULATION ASSAY
MARYAM POURABDOLLAH. University of Ottawa, OTTAWA, ON, Canada

AN UNUSUAL PRESENTATION OF MULTIPLE MYELOMA WITH SPONTANEOUS SUBARACHNOID HEMORRHAGE FROM SKULL BASE INVOLVEMENT AND THROMBOCYTOPENIA: CASE REPORT AND LITERATURE REVIEW
SWAPNIL SURPUR, SAMEER BHIMANI, IFUNANYA EKECHUKWU, TUSHAR ABHINAV, AADHYAA SHENOY, JAMES CORTESE. The Wright Center for GME, Scranton, PA, USA

3:45 - 5:15 PM

THROMBOSIS

ANTITHROMBOSIS STEWARDSHIP: HIGH-IMPACT OPPORTUNITIES TO OPTIMIZE CARE
Chair/Organizer: Allison Burnett, Anne Rose
Oregon Ballroom 203

3:45

OPTIMIZING ANTITHROMBOTIC OVERSIGHT: IMPROVING QUALITY AND SAFETY IN THROMBOSIS CARE
ARTHUR ALLEN.

4:15

THE CLINICAL PHARMACIST: IMPLEMENTATION OF ANTITHROMBOSIS STEWARDSHIP IN PERIOPERATIVE SETTING
TARA LECH.

4:45

THE ANTITHROMBOSIS PROVIDER CHAMPION: HIT AS A CASE STUDY
JORI MAY.

3:45 - 5:15 PM

BASIC SCIENCE

COAGULATION IN TISSUE-SPECIFIC INJURY AND REPAIR
Chair/Organizer: Glaivy Batsuli, Anandi Krishnan
Oregon Ballroom 201

3:45

ROLE OF FIBRINOGEN IN LIVER INJURY
LAUREN POOLE.

4:15

MITOCHONDRIAL CONTROL OF PROCOAGULANT PLATELETS IN VASCULAR INJURY AND REPAIR
JOE ASLAN.

4:45

PLATELETS IN WOUND HEALING
DANIELLE COENEN.

3:45 - 5:15 PM

HEMOSTASIS / LABORATORY

NEW THERAPEUTIC TARGETS FOR REBALANCED HEMOSTASIS: CLINICAL AND LABORATORY IMPLICATIONS
Chair/Organizer: Karen Moser, Kritin Maher
Oregon Ballroom 204

3:45

CLINICAL CONSIDERATIONS IN SELECTION OF NEWER HEMOPHILIA TREATMENTS
ANGELA WEYAND.

4:15

LABORATORY TESTING FOR PATIENTS ON EMICIZUMAB: CASE-BASED DISCUSSION AND COMMON CHALLENGES IN MONITORING
RAJIV PRUTHI.

4:45

LESSONS FROM CLINICAL TRIALS ON MONITORING ANTITHROMBIN ACTIVITY IN THE SETTING OF FITUSIRAN THERAPY
GUY YOUNG.

5:30 - 6:30 PM

SATELLITE SYMPOSIUM

BRIDGING THE GAPS: SCIENTIFIC UPDATES IN ITP, ITTP, AND WAIHA (SPONSORED BY SANOFI)
B113-114

Immune-mediated hematologic disordersincluding Immune Thrombocytopenic Purpura (ITP), warm Autoimmune Hemolytic Anemia (wAIHA), and immune Thrombotic Thrombocytopenic Purpura (iTTP)present significant diagnostic and therapeutic challenges in contemporary hematology practice. This symposium addresses the most recent updates in immune-mediated hematologic disorders.

RETHINKING HEMOPHILIA A MANAGEMENT: BALANCING BLEED PROTECTION AND ADMINISTRATION CONSIDERATIONS (SPONSORED BY NOVO NORDISK)
B115-116

Despite advancements in hemophilia A management, trade-offs remain: patients often choose between compromising bleed protection or accepting administration-related challenges. This program will reveal real-world data on these unspoken challenges and discuss strategies to identify barriers and enable more effective shared decision-making.